Literature DB >> 23183883

100 years of Lewy pathology.

Michel Goedert1, Maria Grazia Spillantini, Kelly Del Tredici, Heiko Braak.   

Abstract

In 1817, James Parkinson described the symptoms of the shaking palsy, a disease that was subsequently defined in greater detail, and named after Parkinson, by Jean-Martin Charcot. Parkinson expected that the publication of his monograph would lead to a rapid elucidation of the anatomical substrate of the shaking palsy; in the event, this process took almost a century. In 1912, Fritz Heinrich Lewy identified the protein aggregates that define Parkinson disease (PD) in some brain regions outside the substantia nigra. In 1919, Konstantin Nikolaevich Tretiakoff found similar aggregates in the substantia nigra and named them after Lewy. In the 1990s, α-synuclein was identified as the main constituent of the Lewy pathology, and its aggregation was shown to be central to PD, dementia with Lewy bodies, and multiple system atrophy. In 2003, a staging scheme for idiopathic PD was introduced, according to which α-synuclein pathology originates in the dorsal motor nucleus of the vagal nerve and progresses from there to other brain regions, including the substantia nigra. In this article, we review the relevance of Lewy's discovery 100 years ago for the current understanding of PD and related disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183883     DOI: 10.1038/nrneurol.2012.242

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  146 in total

1.  Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease.

Authors:  Satoshi Orimo; Takeshi Amino; Yoshinori Itoh; Atsushi Takahashi; Tohru Kojo; Toshiki Uchihara; Kuniaki Tsuchiya; Fumiaki Mori; Koichi Wakabayashi; Hitoshi Takahashi
Journal:  Acta Neuropathol       Date:  2005-06-03       Impact factor: 17.088

Review 2.  Pathology associated with sporadic Parkinson's disease--where does it end?

Authors:  H Braak; C M Müller; U Rüb; H Ackermann; H Bratzke; R A I de Vos; K Del Tredici
Journal:  J Neural Transm Suppl       Date:  2006

3.  Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations.

Authors:  Frank Soldner; Josée Laganière; Albert W Cheng; Dirk Hockemeyer; Qing Gao; Raaji Alagappan; Vikram Khurana; Lawrence I Golbe; Richard H Myers; Susan Lindquist; Lei Zhang; Dmitry Guschin; Lauren K Fong; B Joseph Vu; Xiangdong Meng; Fyodor D Urnov; Edward J Rebar; Philip D Gregory; H Steve Zhang; Rudolf Jaenisch
Journal:  Cell       Date:  2011-07-14       Impact factor: 41.582

4.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

5.  Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease.

Authors:  A L Benabid; P Pollak; A Louveau; S Henry; J de Rougemont
Journal:  Appl Neurophysiol       Date:  1987

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons.

Authors:  Heiko Braak; Magdalena Sastre; Jürgen R E Bohl; Rob A I de Vos; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2007-02-09       Impact factor: 17.088

8.  Occurrence of Parkinson's syndrome in type I Gaucher disease.

Authors:  O Neudorfer; N Giladi; D Elstein; A Abrahamov; T Turezkite; E Aghai; A Reches; B Bembi; A Zimran
Journal:  QJM       Date:  1996-09

9.  Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors:  John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

10.  Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study.

Authors:  Estifanos Ghebremedhin; Kelly Del Tredici; James W Langston; Heiko Braak
Journal:  Acta Neuropathol       Date:  2009-10-03       Impact factor: 17.088

View more
  371 in total

1.  AggreCount: an unbiased image analysis tool for identifying and quantifying cellular aggregates in a spatially defined manner.

Authors:  Jacob Aaron Klickstein; Sirisha Mukkavalli; Malavika Raman
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

Review 2.  Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives.

Authors:  Khosro Jamebozorgi; Eskandar Taghizadeh; Daryoush Rostami; Hosein Pormasoumi; George E Barreto; Seyed Mohammad Gheibi Hayat; Amirhossein Sahebkar
Journal:  Mol Neurobiol       Date:  2018-11-05       Impact factor: 5.590

3.  Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease.

Authors:  Saurav Brahmachari; Saebom Lee; Sangjune Kim; Changqing Yuan; Senthilkumar S Karuppagounder; Preston Ge; Rosa Shi; Esther J Kim; Alex Liu; Donghoon Kim; Stephan Quintin; Haisong Jiang; Manoj Kumar; Seung Pil Yun; Tae-In Kam; Xiaobo Mao; Yunjong Lee; Deborah A Swing; Lino Tessarollo; Han Seok Ko; Valina L Dawson; Ted M Dawson
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

4.  Assembly of α-synuclein aggregates on phospholipid bilayers.

Authors:  Zhengjian Lv; Mohtadin Hashemi; Siddhartha Banerjee; Karen Zagorski; Jean-Christophe Rochet; Yuri L Lyubchenko
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2019-06-19       Impact factor: 3.036

5.  Parkinson's disease-related phosphorylation at Tyr39 rearranges α-synuclein amyloid fibril structure revealed by cryo-EM.

Authors:  Kun Zhao; Yeh-Jun Lim; Zhenying Liu; Houfang Long; Yunpeng Sun; Jin-Jian Hu; Chunyu Zhao; Youqi Tao; Xing Zhang; Dan Li; Yan-Mei Li; Cong Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-31       Impact factor: 11.205

6.  Structural basis of the interplay between α-synuclein and Tau in regulating pathological amyloid aggregation.

Authors:  Jinxia Lu; Shengnan Zhang; Xiaojuan Ma; Chunyu Jia; Zhenying Liu; Chengan Huang; Cong Liu; Dan Li
Journal:  J Biol Chem       Date:  2020-04-13       Impact factor: 5.157

Review 7.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

8.  Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.

Authors:  Mechelle M Lewis; Guangwei Du; Jennifer Baccon; Amanda M Snyder; Ben Murie; Felicia Cooper; Christy Stetter; Lan Kong; Christopher Sica; Richard B Mailman; James R Connor; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

Review 9.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

Review 10.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.